
    the study was closed as the data received to date did not support continuation of the study.
  
['healthy']
['al-794', 'placebo']

        Inclusion Criteria:

          -  Participant has provided written informed consent

          -  In the Investigator's opinion, the participant is able to understand and comply with
             protocol requirements, instructions, and protocol-stated restrictions and is likely to
             complete the study as planned

          -  Participant is deemed healthy on the basis of physical examination, medical history,
             vital signs, 12-lead electrocardiogram (ECG), and clinical laboratory tests performed
             at screening

          -  Body mass index (BMI) 18 - 32 kilogram per meter square (kg/m^2), inclusive. The
             minimum weight is 50 kilogram (kg). No more than 25 percent (%) of participants may be
             enrolled with a BMI greater than or equal to (>=) 30 kg/m^2

          -  Female participants must have a negative serum (beta-human chorionic gonadotropin
             [beta-hCG]) pregnancy test at screening and on Day -1 (admission)

        Exclusion Criteria:

          -  Female who is pregnant as confirmed by a positive beta-human chorionic gonadotropin
             (beta-hCG) laboratory test, or who was pregnant within 6 months prior to study start,
             or who is breast-feeding, or who is planning to become pregnant from signing of the
             informed consent form (ICF) until 90 days after the last dose of study drug

          -  Male whose female partner is pregnant or contemplating pregnancy from the date of
             screening until 90 days after their last dose of study drug

          -  Participant with one or more of the following laboratory abnormalities at screening:
             aspartate aminotransferase (AST) or alanine aminotransferase (ALT) >= 1.2*upper limit
             of normal (ULN); Alkaline phosphatase (ALP) >= 1.2*ULN; Total bilirubin >= 1.2*ULN;
             Clinically significant laboratory abnormalities or abnormalities which are deemed to
             interfere with the ability to interpret study data

          -  Creatinine clearance less than (<) 90 milliliter per minute (mL/min) (using the
             Chronic Kidney Disease Epidemiology Collaboration [CKD-EPI] equation)

          -  Positive screening test for human immunodeficiency virus type 1 (HIV-1) or HIV-2
             antibody, or for current hepatitis A infection (confirmed by hepatitis A antibody
             immunoglobulin M [IgM]), or hepatitis B virus (HBV) infection (confirmed by hepatitis
             B surface antigen [HBsAg]), or hepatitis C virus (HCV) infection (confirmed by HCV
             antibody) at screening
      